Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00415454 · ClinicalTrials.gov registry record · Phase 1
Study Combining Suicide Gene Therapy With Chemoradiotherapy in the Treatment of Non-Metastatic Pancreatic Adenocarcinoma
A Phase 1 study, sponsored by Henry Ford Health System.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00415454: Clinical Trial Phase 1 study, sponsored by Henry Ford Health System.
NCT00415454 is a Phase 1 study that was terminated before completion, run by Henry Ford Health System. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00415454, a Phase 1 study, was terminated before completion, sponsored by Henry Ford Health System.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The primary purpose of this phase I study is to determine the safety of combining replication-competent adenovirus-mediated suicide gene therapy with chemoradiotherapy in patients with non-metastatic pancreatic cancer.
Interventions
- GENETIC Ad5-yCD/mutTKSR39rep-ADP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2006-11 |
| Phase | Phase 1 |
Why NCT00415454 stopped before completion
NCT00415454 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which Ad5-yCD/mutTKSR39rep-ADP is the first listed.
NCT00415454 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00415454 about?
NCT00415454 is a clinical study titled "Study Combining Suicide Gene Therapy With Chemoradiotherapy in the Treatment of Non-Metastatic Pancreatic Adenocarcinoma". The primary purpose of this phase I study is to determine the safety of combining replication-competent adenovirus-mediated suicide gene therapy with chemoradiotherapy in patients with non-metastatic pancreatic cancer.
What is the current status of trial NCT00415454?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2006-11.
What interventions are being tested in trial NCT00415454?
The interventions under investigation include: Ad5-yCD/mutTKSR39rep-ADP (GENETIC).
Who is sponsoring clinical trial NCT00415454?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00415454's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia